Time of issue:2019-07-09 00:00:00
- Categories:Our science
- Time of issue:2019-05-29 00:00:00
1.More than 500 cases of exploratory clinical research have been completed in hematological tumor, and the clinical efficacy of The CAR-T products of Bio-raid is better than international.
(1) CD19+CD22 CAR-T cell sequential therapy
The first CD19+CD22 CAR-T cell sequential therapy can target CD19 and CD22, respectively, to avoid the recurrence caused by the escape mechanism of cancer cells under the pressure of single-target CAR-T cell therapy. The clinical efficacy is better than international.
(2) CD19/22 Dual-CAR-T
CD19/22 Dual-CAR-T treatment of diffuse large B lymphoma whi